drugset
drugset / Trial / NCT02732418

Lower Dose Depo Provera® Contraceptive Injection

NCT02732418 ↗

Phase 1 Completed 60 enrolled FHI 360
RandomizedParallel-groupSingle-blindPrevention

Summary

This is a randomized, partially-blinded, multi-center, parallel-group study to evaluate and compare the PD and PK of MPA after a single SC injection of either 45 mg/0.3 mL, 75 mg/0.5 mL or 105 mg/0.7 mL of Depo-Provera CI, and one cycle of Depo-subQ 104 use when injected in the abdomen, in women of reproductive age with confirmed ovulatory baseline cycle

Timeline

Start
2016-12-02
Primary completion
2018-05-15
Completion
2018-05-15

Drugs

EvaluationDrugModalityDoseRoute
Subject medroxyprogesterone acetate Other / unclassified 45 mg Subcutaneous
Subject medroxyprogesterone acetate Other / unclassified 75 mg Subcutaneous
Subject medroxyprogesterone acetate Other / unclassified 104 mg Subcutaneous
Subject medroxyprogesterone acetate Other / unclassified 105 mg Subcutaneous

Indications

No indication recorded.